Interview with Dr James Garner, CEO of Kazia Therapeutics

XR-17 is Vivesto’s proprietary delivery platform

Vivesto published its Q1 2022 report on May 25, 2022, at 08.00 am CET.

The Share

Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program

Annual Report 2021